Durães Fernando, Sousa Emília
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal.
Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. doi: 10.3390/ph12020063.
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.
奥马环素（Nuzyra®）是一种新型氨甲基环素，于2018年获得美国食品药品监督管理局批准，属于四环素类抗菌药物。它可用于治疗社区获得性肺炎以及急性细菌性皮肤和皮肤结构感染。该药物由Paratek制药公司研发并实现商业化。它是一种半合成化合物，由米诺环素衍生而来，能够规避广泛存在的外排和靶点保护抗菌耐药机制，并且已在多种细菌中显示出活性。
